VP, Global Drug Development Program Lead at Vor Bio

Boston, Massachusetts, United States

Vor Bio Logo
Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries

Requirements

  • Medical Degree (MD) required; specialization in autoimmune, neurology or neuromuscular
  • Minimum 15 years of experience in pharmaceutical/biotech drug development

Responsibilities

  • Lead the overall development strategy for assigned drug programs, ensuring clear objectives, timelines, and deliverables are established and met
  • Provide scientific leadership across early-stage development through post-marketing activities
  • Represent the company in external forums, including scientific conferences and regulatory discussions
  • Oversee clinical trial design, execution, and data interpretation
  • Lead site selection, patient enrollment, and medical monitoring
  • Ensure safety oversight and pharmacovigilance across all clinical programs
  • Guide regulatory submission planning and execution, ensuring compliance with global requirements and facilitating interactions with health authorities; partner with regulatory affairs on submissions including INDs, NDAs, BLAs, and CTAs
  • Build and mentor a high-performing medical team, fostering a culture of innovation and collaboration
  • Collaborate with clinical, regulatory, medical, commercial, manufacturing, and other functional teams to integrate activities and resolve challenges throughout the development lifecycle
  • Develop and maintain comprehensive program plans, including risk assessments, mitigation strategies, and contingency plans to address potential obstacles
  • Serve as the primary contact for internal and external stakeholders, including senior management, global project teams, external partners, and regulatory authorities
  • Provide regular updates to leadership and teams, preparing high-quality presentations, reports, and documentation to support decision-making
  • Oversee program budgets, resource allocation, and financial forecasting to ensure efficient use of assets and adherence to organizational priorities
  • Track program progress against milestones, proactively identify issues, and implement corrective actions to maintain momentum and achieve objectives
  • Provide oversight of Pharmacology, Toxicology, Medical Writing, and Biometrics

Skills

Drug Development
Clinical Trials
Regulatory Compliance
Clinical Operations
Pharmacology
Toxicology
Medical Writing
Biometrics
Strategic Planning
Cross-Functional Leadership

Vor Bio

Develops targeted therapies for blood cancers

About Vor Bio

Vor Biopharma focuses on developing treatments for blood cancers, particularly Acute Myeloid Leukemia (AML). Their approach is designed to protect healthy cells while specifically targeting and eliminating cancerous cells. This method aims to improve the effectiveness of blood cancer treatments. Vor Biopharma serves patients with blood cancers, their caregivers, and medical professionals in hospitals and oncology centers. What sets Vor Biopharma apart from competitors is their strong emphasis on research and development, investing significantly in scientific research to create a proprietary platform and pipeline of therapies. They generate revenue through partnerships with other pharmaceutical companies and licensing agreements, with the goal of commercializing their therapies after obtaining regulatory approval. The company's mission is to transform the treatment landscape for blood cancers by providing innovative therapies that prioritize patient safety and efficacy.

Cambridge, MassachusettsHeadquarters
2015Year Founded
$147.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Vacation
Parental Leave
401(k) Retirement Plan
401(k) Company Match
Commuter Benefits

Risks

Significant YTD price decline of -62.76% may affect investor confidence.
Key clinical trial data updates are not expected until 2025, causing uncertainty.
Increased competition from companies like Editas Medicine poses potential conflicts.

Differentiation

Vor Bio focuses on protecting healthy cells while targeting cancerous ones.
The company specializes in innovative treatments for blood cancers like AML.
Vor Bio's approach aligns with the rise of personalized medicine.

Upsides

Recent $55.6M funding supports clinical trials and extends cash runway to 2025.
FDA's acceptance of gene therapies may ease approval for Vor Bio's treatments.
Advancements in CRISPR technology enhance precision of Vor Bio's gene editing.

Land your dream remote job 3x faster with AI